Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
N Z Med J ; 125(1353): 47-58, 2012 Apr 20.
Artigo em Inglês | MEDLINE | ID: mdl-22522271

RESUMO

AIM: To compare the performance, in terms of specificity for cortisol excess, of late-night salivary cortisol with 24-hour urine-free cortisol (24hr UFC) and overnight 1mg dexamethasone suppression test (1mg DST) in a group of obese T2DM patients. METHODS: Forty obese patients with T2DM without clinical features of Cushing's syndrome were recruited. Plasma, urinary and salivary cortisol were measured directly by an enzyme-linked immunosorbent assay using monoclonal antibodies. The specificities of the three tests using various cutoffs were calculated and compared, employing the assumption that none of the patients had hypercortisolism. RESULTS: The patients had a mean age and BMI of 56 years (range 31-75) and 37 kg/m² (31-56) respectively. All 40 provided late-night salivary cortisol samples. Thirty-eight patients completed all three tests. Two patients only completed two screening tests. The specificities of late-night salivary cortisol (cutoff 10 nmol/L), 24hr UFC (400 nmol) and 1mg DST (50 nmol/L) were 70% (95% CI 53-83%), 90% (76-97%) and 72% (55-85%) respectively. The specificity of late-night salivary cortisol was significantly less than 24 hr UFC (P=0.039) but not 1mg DST (P>0.99). CONCLUSION: Late-night salivary cortisol has a poor specificity for cortisol excess in obese patients with T2DM with 24 hr UFC showing significantly better specificity in our population.


Assuntos
Síndrome de Cushing/diagnóstico , Diabetes Mellitus Tipo 2/complicações , Hidrocortisona/análise , Obesidade/complicações , Saliva/química , Adulto , Idoso , Síndrome de Cushing/metabolismo , Feminino , Humanos , Hidrocortisona/sangue , Hidrocortisona/urina , Masculino , Pessoa de Meia-Idade , Fatores de Tempo , Urinálise
3.
Ann Clin Biochem ; 48(Pt 3): 286-90, 2011 May.
Artigo em Inglês | MEDLINE | ID: mdl-21441391

RESUMO

We present four cases with clinical and biochemical hypocalcaemia and evidence supportive of hypoparathyroidism. One case had been previously ascribed a diagnosis of idiopathic hypoparathyroidism. Following the detection of relative hypercalciuria, all cases were found to have autosomal dominant hypocalcaemia with hypercalciuria and mutations of the calcium-sensing receptor gene, of which two were novel. Increased awareness of this condition and access to genotyping enables prompt accurate diagnosis and cascade screening of first-degree relatives.


Assuntos
Genes Dominantes/genética , Hipercalciúria/complicações , Hipocalcemia/complicações , Hipocalcemia/genética , Mutação , Receptores de Detecção de Cálcio/genética , Adulto , Sequência de Bases , Criança , Feminino , Humanos , Hipocalcemia/diagnóstico , Hipotireoidismo/complicações , Masculino , Adulto Jovem
4.
J Clin Endocrinol Metab ; 94(7): 2332-7, 2009 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-19366850

RESUMO

CONTEXT: Parenteral iron administration has been associated with hypophosphatemia. Fibroblast growth factor 23 (FGF23) has a physiological role in phosphate homeostasis via suppression of 25-hydroxyvitamin D [25(OH)D] activation and promotion of phosphaturia. We recently reported a case of iron-induced hypophosphatemic osteomalacia associated with marked FGF23 elevation. OBJECTIVE: Our objective was to prospectively investigate the effect of parenteral iron polymaltose on phosphate homeostasis and to determine whether any observed change was related to alterations in circulating FGF23. DESIGN, SETTING, AND PARTICIPANTS: Eight medical outpatients prescribed iv iron polymaltose were recruited. Plasma phosphate, 25(OH)D, 1,25-dihydroxyvitamin D [1,25(OH)(2)D], PTH, FGF23, and urinary tubular reabsorption of phosphate were measured prior to iron administration and then weekly for a minimum of 3 wk. RESULTS: Plasma phosphate fell from 3.4 +/- 0.6 mg/dl at baseline to 1.8 +/- 0.6 mg/dl at wk 1 (P < 0.0001) associated with a fall in percentage tubular reabsorption of phosphate (90 +/- 4.8 to 68 +/- 13; P < 0.001) and 1,25(OH)(2)D (54 +/- 25 to 9 +/- 8 pg/ml; P < 0.001). These indices remained significantly suppressed at wk 2 and 3. 25(OH)D levels were unchanged. FGF23 increased significantly from 43.5 pg/ml at baseline to 177 pg/ml at wk 1 (P < 0.001) with levels correlating with both serum phosphate (R = -0.74; P <0.05) and 1,25(OH)(2)D (R = -0.71; P < 0.05). CONCLUSION: Parenteral iron suppresses renal tubular phosphate reabsorption and 1alpha-hydroxylation of vitamin D resulting in hypophosphatemia. Our data suggest that this is mediated by an increase in FGF23.


Assuntos
Compostos Férricos/efeitos adversos , Fatores de Crescimento de Fibroblastos/sangue , Hipofosfatemia/induzido quimicamente , Ferro/efeitos adversos , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Compostos Férricos/administração & dosagem , Fator de Crescimento de Fibroblastos 23 , Fatores de Crescimento de Fibroblastos/metabolismo , Fatores de Crescimento de Fibroblastos/fisiologia , Humanos , Hidroxilação/efeitos dos fármacos , Hipofosfatemia/sangue , Injeções Intravenosas , Ferro/administração & dosagem , Ferro/química , Pessoa de Meia-Idade , Hormônio Paratireóideo/sangue , Fosfatos/sangue , Regulação para Cima , Vitamina D/análogos & derivados , Vitamina D/sangue , Vitamina D/metabolismo , Adulto Jovem
5.
Ann Clin Biochem ; 46(Pt 2): 167-9, 2009 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-19151167

RESUMO

Iron-induced renal phosphate wasting, hypophosphataemia and osteomalacia have previously been reported in a small number of Japanese patients receiving parenteral iron sucrose. We report the case history of a European male who, as a result of regular intravenous iron polymaltose, developed prolonged hypophosphataemia complicated by widespread insufficiency fractures. The pathogenesis of this complication remains unknown however our novel finding of a marked elevation in fibroblast growth factor 23 (FGF23), which normalized after ceasing parenteral iron, suggests an important and previously unreported effect of iron on FGF23 homeostasis.


Assuntos
Compostos Férricos/efeitos adversos , Fatores de Crescimento de Fibroblastos/metabolismo , Hipofosfatemia/induzido quimicamente , Osteomalacia/induzido quimicamente , Adulto , Fator de Crescimento de Fibroblastos 23 , Humanos , Infusões Intravenosas , Masculino
6.
J Clin Endocrinol Metab ; 93(11): 4245-53, 2008 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-18697868

RESUMO

CONTEXT: The diagnostic value of tests for detecting hypothalamic-pituitary adrenal insufficiency (HPAI) is controversial. OBJECTIVE: Our objective was to compare standard-dose and low-dose corticotropin tests for diagnosing HPAI. DATA SOURCES: We searched the PubMed database from 1966-2006 for studies reporting diagnostic value of standard-dose or low-dose corticotropin tests, with patient-level data obtained from original investigators. STUDY SELECTION: Eligible studies had more than 10 patients. All subjects were evaluated because of suspicion for chronic HPAI, and patient-level data were available. We excluded studies with no accepted reference standard for HPAI (insulin hypoglycemia or metyrapone test) if test subjects were in the intensive care unit or if only normal healthy subjects were used as controls. DATA EXTRACTION: We constructed receiver operator characteristic (ROC) curves using patient-level data from each study and then merged results to create summary ROC curves, adjusting for study size and cortisol assay method. Diagnostic value of tests was measured by calculating area under the ROC curve (AUC) and likelihood ratios. DATA SYNTHESIS: Patient-level data from 13 of 23 studies (57%; 679 subjects) were included in the metaanalysis. The AUC were as follows: low-dose corticotropin test, 0.92 (95% confidence interval 0.89-0.94), and standard-dose corticotropin test, 0.79 (95% confidence interval 0.74-0.84). Among patients with paired data (seven studies, 254 subjects), diagnostic value of low-dose corticotropin test was superior to standard-dose test (AUC 0.94 and 0.85, respectively; P<0.001). CONCLUSIONS: Low-dose corticotropin test was superior to standard-dose test for diagnosing chronic HPAI, although it has technical limitations.


Assuntos
Doenças das Glândulas Suprarrenais/diagnóstico , Hormônio Adrenocorticotrópico/sangue , Doenças Hipotalâmicas/diagnóstico , Doenças da Hipófise/diagnóstico , Hormônio Adrenocorticotrópico/metabolismo , Adulto , Criança , Cosintropina/farmacologia , Jejum , Glucocorticoides/efeitos adversos , Humanos , Hidrocortisona/sangue , Sistema Hipotálamo-Hipofisário , Curva ROC , Reprodutibilidade dos Testes
7.
J Endocrinol ; 192(2): 313-23, 2007 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-17283231

RESUMO

Ghrelin is a 28 amino acid stomach peptide, derived from proghrelin(1-94), that stimulates GH release, appetite and adipose deposition. Recently, a peptide derived from proghrelin(53-75) -- also known as obestatin -- has been reported to be a physiological antagonist of ghrelin in the rat. Using four specific RIAs, we provide the first characterisation of proghrelin(1-94) peptides in human plasma, their modulation by metabolic manipulation and their distribution in mammalian tissues. ghrelin(1-28) immunoreactivity (IR) in human plasma and rat plasma/stomach consisted of major des-octanoyl and minor octanoylated forms, as determined by HPLC/RIA. Human plasma ghrelin(1-28) IR was significantly suppressed by food intake, oral glucose and 1 mg s.c. glucagon administration. ghrelin(1-28) IR and proghrelin(29-94) IR peptide distributions in the rat indicated that the stomach and gastrointestinal tract contain the highest amounts of the peptides. Human and rat plasma and rat stomach extracts contained a major IR peak of proghrelin(29-94)-like peptide as determined by HPLC/RIA, whereas no obestatin IR was observed. Human plasma proghrelin(29-94)-like IR positively correlated with ghrelin(1-28) IR, was significantly suppressed by food intake and oral glucose and shared with ghrelin(1-28) IR a negative correlation with body mass index. We found no evidence for the existence of obestatin as a unique, endogenous peptide. Rather, our data suggest that circulating and stored peptides derived from the carboxyl terminal of proghrelin (C-ghrelin) are consistent in length with proghrelin(29-94) and respond to metabolic manipulation, at least in man, in similar fashion to ghrelin(1-28).


Assuntos
Trato Gastrointestinal/química , Mamíferos/metabolismo , Hormônios Peptídicos/análise , Precursores de Proteínas/análise , Adulto , Idoso , Animais , Glicemia/análise , Cromatografia Líquida de Alta Pressão/métodos , Jejum , Feminino , Grelina , Glucagon/farmacologia , Glucose/administração & dosagem , Humanos , Insulina/sangue , Intestinos/química , Masculino , Pessoa de Meia-Idade , Fragmentos de Peptídeos/análise , Fragmentos de Peptídeos/sangue , Hormônios Peptídicos/sangue , Precursores de Proteínas/sangue , Radioimunoensaio/métodos , Ratos , Ratos Sprague-Dawley , Estômago/química
8.
Clin Biochem ; 39(10): 1028-34, 2006 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-16919253

RESUMO

OBJECTIVE: To examine whether use of the Beckman Coulter Access Prolactin (PRL) assay, which has low reactivity with macro-PRL, obviates the need for screening hyperprolactinemic samples. DESIGN AND METHODS: Samples from 1020 hyperprolactinemic individuals and 401 healthy volunteers were treated with polyethylene glycol (PEG). Macro-PRL was assessed from (1) percent PRL recovery, using cut-off values derived by gel filtration chromatography (GFC) and (2) significant (p<0.05) normalisation of PRL following PEG. RESULTS: PRL recovery was similar in volunteer and hyperprolactinemic samples (mean+/-SD 101+/-13% and 101+/-19%, respectively). In hyperprolactinemic samples, macro-PRL was identified from PRL recovery in 9.7%, although levels were moderate to high in only 3.9%. The total PRL normalised following PEG in 7.4%. Correlations of PRL recovery with the proportions of macro-, big- and monomeric PRL following GFC (n=30 samples, range of PRL and macro-PRL levels) were -0.89, -0.20 and 0.92, respectively. The big-PRL content was 0-28%. Regression analysis suggested that PEG precipitated both macro-PRL and big-PRL. CONCLUSIONS: Using the Access assay, macro-PRL can cause apparent hyperprolactinemia and big-PRL may cause misclassification of individuals. Screening using PEG is applicable to assays with low macro-PRL reactivity provided specific reference values are derived.


Assuntos
Equipamentos e Provisões , Hiperprolactinemia/diagnóstico , Prolactina/sangue , Cromatografia em Gel , Erros de Diagnóstico , Humanos
9.
J Hypertens ; 21(5): 921-6, 2003 May.
Artigo em Inglês | MEDLINE | ID: mdl-12714866

RESUMO

OBJECTIVE: To determine the relationship between R563Q, a mutation of the renal epithelial sodium channel, and hypertension. METHODS: Hypertensive patients with low renin and aldosterone, hypokalemia or resistant hypertension were selected for DNA analysis. Genomic DNA encoding the C-terminal domain of the epithelial sodium channel beta subunit from hypertensives and controls was amplified by polymerase chain reaction and screened for the R563Q mutation by digestion with Sfc1 restriction enzyme, or sequenced. RESULTS: A previously undescribed mutation, R563Q, of the beta epithelial sodium channel was found in 10 of 139 black hypertensives, but was not present in any of 103 black normotensives, a significant (P = 0.0058) difference in frequency. The frequency of the mutation in the subgroup of black low-renin, low-aldosterone hypertensives (four of 14) was significantly (P = 0.0001) greater than in normotensives, and was also greater (P = 0.041) than in normal-high renin hypertensives, suggesting that R563Q is an activating mutation of the epithelial sodium channel. R563Q was also found in seven out of 250 mixed ancestry hypertensives, and was significantly (P = 0.017) associated with low-renin, low-aldosterone hypertension in this population group. The mutation was found in one of 100 mixed ancestry normotensives but not in any of 136 white hypertensives. Of the 18 R563Q patients, 11 had severe hypertension, leading to renal failure in two cases, while only two had hypokalaemia. CONCLUSIONS: R563Q, a new variant of the beta epithelial sodium channel, is associated with low-renin, low-aldosterone hypertension, in South African black and mixed-ancestry patients. Only a minority of individuals with the R563Q allelle fully express the Liddle's syndrome phenotype.


Assuntos
Aldosterona/sangue , Hipertensão/sangue , Hipertensão/genética , Mutação Puntual/genética , Renina/sangue , Canais de Sódio/genética , Canais de Sódio/metabolismo , Adulto , Idoso , Aldosterona/genética , Sequência de Aminoácidos , Biomarcadores/sangue , População Negra/etnologia , População Negra/genética , Feminino , Predisposição Genética para Doença/genética , Insuficiência Cardíaca/etiologia , Heterozigoto , Humanos , Hipertensão/complicações , Hipopotassemia/sangue , Hipopotassemia/genética , Falência Renal Crônica/etiologia , Masculino , Pessoa de Meia-Idade , Reação em Cadeia da Polimerase , Renina/genética , Índice de Gravidade de Doença , África do Sul/etnologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...